1.220

-0.010 (-0.81%)
Range 1.200 - 1.260   (5%)
Open 1.240
Previous Close 1.230
Buy Price 1.210
Buy Volume 270
Sell Price 1.220
Sell Volume 407
Volume 3,033,451
Value -
Remark
Measurement Type Value
EPS (USD) -0.237
Trailing EPS (USD) -0.273
NAV (USD) 0.632
Cash In Hand (USD) 0.1
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 1.932
Price / Cash In Hand 12.188
Issued & Paid-up Shares 318,568,000
Treasury Shares -
Market Cap (M) 388.653
Par Value (USD) n.a.
Beta - 75 Days 0.443
R-Squared - 75 Days(%) 0.78
Beta - 500 Days 0.783
R-Squared - 500 Days(%) 10.62
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 31 Jul 2021 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Earnings

Release Date 05 Aug 2021
View All Events

About GERON CORP

Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets.

Loading Chart...